Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Eisai: FDA allows initial dose of Leqembi for at-home use

The FDA has approved the initial dose of Eisai’s Alzheimer treatment Leqembi for subcutaneous at-home use, allowing patients or caregivers to administer the therapy themselves. Until now treatment began with intravenous infusions in clinics, with maintenance therapy following after 18 months. The approval is likely to increase accessibility and acceptance and to set Leqembi apart from intravenously administered competing drugs. Possible side effects include injection-site reactions such as redness, swelling, rash, pain or bruising. » More on de.investing.com
Eisai unveils conservative three-year plan targeting ¥1 trillion in revenue and ¥90 billion operating profit

Eisai has presented a three-year plan through March 2029 aiming for ¥1 trillion in revenue and ¥90 billion in operating profit. The revenue target is roughly in line with consensus (¥972 billion), while the operating profit goal is below analysts’ estimates (¥101.8 billion). The company specifies target revenues of ¥300 billion for Leqembi, ¥250 billion for Lenvima and ¥100 billion for Dayvigo, and expects a cost of goods sold ratio of 30% (consensus 23%), which it attributes to a worse product mix. » More on de.investing.com
Eisai posts record revenue, operating profit falls sharply

Eisai reported record revenue of JPY 825.4 billion (+4.6%) for Q4 of fiscal 2025, while operating profit fell 18.8% to JPY 44.1 billion and net profit fell 17% to JPY 38.6 billion. Core operating profit more than doubled to JPY 50.1 billion, driven by the pharmaceutical business with products such as LEQEMBI, DAYVIGO and LENVIMA. The company attributed the profit declines to strategic decisions against out-licensing and unexpected restructuring costs in Europe. For 2026, Eisai forecasts further growth, including expected sales of JPY 345 billion for LENVIMA and JPY 143.5 billion for LEQEMBI. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Eisai has already paid €0.43 in dividends. The last payout was in June.

Financials

In the last quarter, Eisai had revenue of €1.26bn and net profit of €98.28m

(EUR)	June 2026	YoY
Revenue	1.26bn	5.59%
Gross profit	987.18m	4.55%
Net profit	98.28m	15.08%
EBITDA	183.82m	5.63%

Fundamentals

Metric	Value
Market capitalization	€8.14bn
Number of shares	282.24m
52-week high/low	€29.79 - €20.79
Dividend yield	2.95%
Dividends TTM	€0.87
Next dividend	€0.45
Beta	-0.05
P/E ratio	33.82
PEG ratio	-2.14
P/B ratio	1.58
P/S ratio	1.67

Company profile

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.